Spots Global Cancer Trial Database for gliosarcoma
Every month we try and update this database with for gliosarcoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme | NCT00672243 | Glioblastoma Gliosarcoma | Erlotinib + sir... | 18 Years - | Duke University | |
| Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma | NCT02168270 | Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... Glioblastoma Gliosarcoma | ascorbic acid temozolomide quality-of-life... laboratory biom... | 19 Years - | University of Nebraska | |
| Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma | NCT04091503 | Glioma, Maligna... Gliosarcoma Astrocytoma of ... | Intranasal Modi... | 21 Years - 70 Years | Center Trials & Treatment Europe | |
| Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma | NCT00365222 | Glioblastoma Gliosarcoma | Temozolomide | 70 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Ph I Dasatinib + Erlotinib in Recurrent MG | NCT00609999 | Glioblastoma Gliosarcoma | Erlotinib and D... | 18 Years - | Duke University | |
| Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma | NCT00365222 | Glioblastoma Gliosarcoma | Temozolomide | 70 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma | NCT03197506 | Glioblastoma Gliosarcoma Supratentorial ... | External Beam R... Laboratory Biom... Pembrolizumab Radiation Thera... Temozolomide Therapeutic Con... | 18 Years - | Mayo Clinic | |
| Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | NCT01814813 | Recurrent Gliob... Recurrent Adult... Gliosarcoma | HSPPC-96 bevacizumab | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM | NCT00597493 | Recurrent Gliob... | Sorafenib and T... | 18 Years - | Duke University | |
| Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma | NCT00979173 | Glioma | AC480 | 18 Years - | Duke University | |
| Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma | NCT01582152 | Brain Neoplasms Central Nervous... | TPI287 Bevacizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer | NCT03107780 | Glioblastoma Gliosarcoma MGMT-Unmethylat... Recurrent Gliob... | Biospecimen Col... Magnetic Resona... Navtemadlin Radiation Thera... | 18 Years - | National Cancer Institute (NCI) | |
| Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM | NCT00612989 | Glioblastoma Gliosarcoma | Temodar and O6-... | 18 Years - | Duke University | |
| Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma | NCT01480479 | Glioblastoma Small Cell Glio... Giant Cell Glio... Gliosarcoma Glioblastoma Wi... | Rindopepimut (C... Temozolomide KLH | 18 Years - | Celldex Therapeutics | |
| Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma | NCT03197506 | Glioblastoma Gliosarcoma Supratentorial ... | External Beam R... Laboratory Biom... Pembrolizumab Radiation Thera... Temozolomide Therapeutic Con... | 18 Years - | Mayo Clinic | |
| Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas | NCT00031083 | Glioblastoma Mu... Anaplastic Astr... Oligoastrocytom... Gliosarcoma | Interferon-beta | 18 Years - | Biogen | |
| Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | NCT02311920 | Gliosarcoma Supratentorial ... | Ipilimumab Laboratory Biom... Nivolumab Temozolomide | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM) | NCT00735436 | Malignant Gliom... Glioblastoma Mu... Gliosarcoma | Gliadel/Avastin... | 18 Years - | Duke University | |
| Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma | NCT03478462 | Pediatric Solid... Pediatric Lymph... Pediatric Brain... DIPG Neuroblastoma Ewing Sarcoma Rhabdomyosarcom... Osteosarcoma | CLR 131 | 2 Years - 25 Years | Cellectar Biosciences, Inc. | |
| AMG 102 and Avastin for Recurrent Malignant Glioma | NCT01113398 | Glioblastoma Mu... Gliosarcoma | AMG 102 Avastin | 18 Years - | Duke University | |
| Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas | NCT00612339 | Glioblastoma Gliosarcoma | Avastin and Tem... | 18 Years - | Duke University | |
| Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma | NCT02599090 | Glioblastoma Gliosarcoma | Temozolomide Radiation Sorafenib | 18 Years - | M.D. Anderson Cancer Center | |
| Natural Progesterone for the Treatment of Recurrent Glioblastoma | NCT05091866 | Gliosarcoma Recurrent Gliob... | Quality-of-Life... Questionnaire A... Therapeutic Pro... | 18 Years - | Emory University | |
| Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme | NCT00672243 | Glioblastoma Gliosarcoma | Erlotinib + sir... | 18 Years - | Duke University | |
| Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | NCT01814813 | Recurrent Gliob... Recurrent Adult... Gliosarcoma | HSPPC-96 bevacizumab | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma | NCT04555577 | Glioblastoma Gliosarcoma | Peposertib Radiation Thera... Resection Temozolomide | 18 Years - | M.D. Anderson Cancer Center | |
| EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas | NCT01257594 | Brain Cancer | erlotinib Cytoreductive S... | 18 Years - | Columbia University | |
| Ph II Bevacizumab + Etoposide for Pts w Recurrent MG | NCT00612430 | Glioblastoma Gliosarcoma | Bevacizumab and... | 18 Years - | Duke University | |
| Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab | NCT02330562 | Malignant Gliom... Glioblastoma | MRZ BEV | 18 Years - | Celgene | |
| Multi-site Validation and Application of a Consensus DSC-MRI Protocol | NCT03401866 | Glioblastoma Mu... Gliosarcoma | DSC-MRI | 18 Years - | St. Joseph's Hospital and Medical Center, Phoenix | |
| Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue | NCT05756985 | Glioblastoma Glioblastoma Mu... Gliosarcoma | Specimen Collec... | 18 Years - | Baptist Health South Florida | |
| Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme | NCT00883298 | Recurrent Gliob... Recurrent Glios... | temozolomide an... | 18 Years - 83 Years | Center for Neurosciences, Tucson | |
| Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer | NCT03107780 | Glioblastoma Gliosarcoma MGMT-Unmethylat... Recurrent Gliob... | Biospecimen Col... Magnetic Resona... Navtemadlin Radiation Thera... | 18 Years - | National Cancer Institute (NCI) | |
| Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | NCT01609790 | Giant Cell Glio... Glioblastoma Gliosarcoma Oligodendroglio... Recurrent Brain... Recurrent Gliob... | Bevacizumab Laboratory Biom... Pharmacological... Placebo Adminis... Trebananib | 18 Years - | National Cancer Institute (NCI) | |
| Bevacizumab Beyond Progression (BBP) | NCT01740258 | Malignant Gliom... Grade 4 Maligna... Glioblastoma Gliosarcoma | Radiation Thera... Temozolomide Bevacizumab | 18 Years - | Duke University | |
| Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | NCT01957956 | Giant Cell Glio... Glioblastoma Gliosarcoma | Laboratory Biom... Malignant Gliom... Temozolomide | 18 Years - | Mayo Clinic | |
| Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research Protocols | NCT00035373 | Glioblatoma Gliosarcoma Anaplastic Astr... Oligodendroglio... Anaplastic Olig... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma | NCT02168270 | Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... Glioblastoma Gliosarcoma | ascorbic acid temozolomide quality-of-life... laboratory biom... | 19 Years - | University of Nebraska | |
| SCH-900105 in Recurrent Glioblastoma | NCT01189513 | Glioblastoma | SCH 900105 | 18 Years - | M.D. Anderson Cancer Center | |
| Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy | NCT01430351 | Glioblastoma Gliosarcoma Supratentorial ... | Mefloquine Memantine Hydro... Metformin Hydro... Temozolomide | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma | NCT05864534 | Newly Diagnosed... Glioblastoma, I... Gliosarcoma Glioblastoma Mu... | Balstilimab Botensilimab Liposomal Doxor... Sonocloud-9 (SC... | 18 Years - | Northwestern University | |
| Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma | NCT03014804 | Giant Cell Glio... Gliosarcoma Oligodendroglio... Recurrent Gliob... Small Cell Glio... | autologous dend... Laboratory Biom... Nivolumab Quality-of-Life... Questionnaire A... | 18 Years - 75 Years | Jonsson Comprehensive Cancer Center | |
| Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan | NCT00613028 | Glioblastoma Gliosarcoma | Temo + Avastin VP-16 + Avastin | 18 Years - | Duke University | |
| Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas | NCT00610571 | Glioblastoma Gliosarcoma Anaplastic Astr... | Oral Topotecan ... | 18 Years - | Duke University | |
| Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan | NCT00613028 | Glioblastoma Gliosarcoma | Temo + Avastin VP-16 + Avastin | 18 Years - | Duke University | |
| Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 | NCT01082926 | Anaplastic Astr... Anaplastic Epen... Anaplastic Meni... Anaplastic Olig... Brain Stem Glio... Ependymoblastom... Giant Cell Glio... Glioblastoma Gliosarcoma Grade III Menin... Meningeal Heman... Mixed Glioma Pineal Gland As... Brain Tumor | therapeutic all... aldesleukin laboratory biom... positron emissi... | 18 Years - 70 Years | City of Hope Medical Center | |
| A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | NCT01837862 | Pilomyxoid Astr... Pilocytic Astro... Glioma, Astrocy... Optic Nerve Gli... Pleomorphic Xan... Glioblastoma Mu... Anaplastic Astr... Gliosarcoma Diffuse Intrins... DIPG Low-grade Gliom... Brainstem Gliom... | Mebendazole Vincristine Carboplatin Temozolomide Bevacizumab Irinotecan | 1 Year - 21 Years | Northwell Health | |
| Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma | NCT04091503 | Glioma, Maligna... Gliosarcoma Astrocytoma of ... | Intranasal Modi... | 21 Years - 70 Years | Center Trials & Treatment Europe | |
| Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I | NCT00671801 | Malignant Gliom... | Irinotecan Lenalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors | NCT02052648 | Glioblastoma Mu... Glioma Gliosarcoma Malignant Brain... | Indoximod Temozolomide Bevacizumab Stereotactic Ra... | 16 Years - | Lumos Pharma | |
| Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma | NCT04216329 | Gliosarcoma Newly Diagnosed Glioblastoma | Selinexor Temozolomide Generic Radiati... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase I/II Cabazitaxel for Recurrent Malignant Glioma | NCT01740570 | Brain Cancer | Cabazitaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I | NCT00671801 | Malignant Gliom... | Irinotecan Lenalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| Sunitinib in Sarcomas of the Central Nervous System | NCT03641326 | Gliosarcoma Central Nervous... | Sunitinib wGT3x-BT | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma | NCT04216329 | Gliosarcoma Newly Diagnosed Glioblastoma | Selinexor Temozolomide Generic Radiati... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma | NCT01149850 | Giant Cell Glio... Glioblastoma Gliosarcoma | bevacizumab temozolomide laboratory biom... immunohistochem... microarray anal... DNA methylation... | 70 Years - | Jonsson Comprehensive Cancer Center | |
| Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) | NCT01110876 | Brain Cancer Glioblastoma Mu... | Vorinostat Erlotinib Temozolomide | 18 Years - | M.D. Anderson Cancer Center | |
| Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma | NCT01095094 | Brain Tumor Anaplastic Astr... Anaplastic Epen... Anaplastic Olig... Brain Stem Glio... Giant Cell Glio... Glioblastoma Gliosarcoma Mixed Glioma | ritonavir lopinavir | 18 Years - | Case Comprehensive Cancer Center | |
| Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | NCT02101905 | Anaplastic Astr... Anaplastic Epen... Anaplastic Olig... Gliosarcoma Mixed Glioma Recurrent Adult... Recurrent Gliob... | Laboratory Biom... Lapatinib Lapatinib Ditos... Pharmacological... Therapeutic Con... | 18 Years - | National Cancer Institute (NCI) | |
| Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma | NCT02743078 | Glioblastoma Glioma Gliosarcoma | Bevacizumab TTFields Therap... | 22 Years - | RTOG Foundation, Inc. | |
| Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma | NCT02661282 | Cytomegalovirus... Glioblastoma Gliosarcoma Malignant Gliom... Recurrent Brain... Recurrent Gliob... | Autologous Cyto... Laboratory Biom... Temozolomide Therapeutic Con... | 18 Years - | M.D. Anderson Cancer Center | |
| Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma | NCT02709226 | Astrocytoma, Gr... Giant Cell Glio... Glioblastoma Mu... Gliosarcoma | Radiation | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) | NCT00671970 | Glioblastoma Gliosarcoma | Bevacizumab and... | 18 Years - | Duke University | |
| Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma | NCT00525525 | Glioblastoma Gliosarcoma | Bevacizumab Tarceva Temozolomide | 18 Years - | University of California, San Francisco | |
| Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | NCT01514201 | Anaplastic Astr... Brain Stem Glio... Childhood Mixed... Fibrillary Astr... Giant Cell Glio... Glioblastoma Gliosarcoma Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... | 3-Dimensional C... Intensity-Modul... Laboratory Biom... Pharmacological... Temozolomide Veliparib | - 21 Years | National Cancer Institute (NCI) | |
| 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma | NCT00114309 | Malignant Gliom... Glioblastoma Mu... GBM Anaplastic Astr... Oligo-Astrocyto... Gliosarcoma | 131-I-TM-601 131I-TM601 | 18 Years - | TransMolecular | |
| Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma | NCT00613054 | Glioblastoma Gliosarcoma | Zactima, Gleeve... | 18 Years - | Duke University | |
| Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00165477 | Glioblastoma Gliosarcoma Malignant Gliom... | lenalidomide Radiation | 18 Years - | Dana-Farber Cancer Institute | |
| Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas | NCT00610571 | Glioblastoma Gliosarcoma Anaplastic Astr... | Oral Topotecan ... | 18 Years - | Duke University | |
| Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED) | NCT00087451 | Malignant Gliom... Glioblastoma Gliosarcoma | AP23573 | 18 Years - | Merck Sharp & Dohme LLC | |
| Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) | NCT00615927 | Glioblastoma Gliosarcoma | Imatinib Mesyla... | 18 Years - | Duke University | |
| Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma | NCT00734526 | Glioblastoma Gliosarcoma | Temozolomide Radiation Sorafenib | 18 Years - | M.D. Anderson Cancer Center | |
| Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma | NCT03014804 | Giant Cell Glio... Gliosarcoma Oligodendroglio... Recurrent Gliob... Small Cell Glio... | autologous dend... Laboratory Biom... Nivolumab Quality-of-Life... Questionnaire A... | 18 Years - 75 Years | Jonsson Comprehensive Cancer Center | |
| PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas | NCT00612651 | Gliosarcoma Glioblastoma Anaplastic Astr... | Temodar and SCH... | 18 Years - | Duke University | |
| Radiosurgery Plus Bevacizumab in Glioblastoma | NCT01086345 | Glioblastoma Gliosarcoma Brain Tumor | radiosurgery bevacizumab irinotecan hydr... | 18 Years - | Case Comprehensive Cancer Center | |
| BIBF 1120 for Recurrent High-Grade Gliomas | NCT01380782 | Glioblastoma Gliosarcoma Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... | BIBF 1120 | 18 Years - | Dana-Farber Cancer Institute | |
| Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma | NCT00936052 | Glioblastomas Gliosarcoma | Hyperbaric Oxyg... | 18 Years - | Neurological Surgery, P.C. | |
| Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma | NCT03275558 | Recurrent Gliob... Gliosarcoma Anaplastic Glio... | Axitinib 1 MG Sunitinib 5 MG Pazopanib 5 MG | 18 Years - 80 Years | Center Trials & Treatment | |
| Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma | NCT01149850 | Giant Cell Glio... Glioblastoma Gliosarcoma | bevacizumab temozolomide laboratory biom... immunohistochem... microarray anal... DNA methylation... | 70 Years - | Jonsson Comprehensive Cancer Center | |
| Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma | NCT05095376 | Glioblastoma Gliosarcoma | Lomustine Photon Beam Rad... Quality-of-Life... Questionnaire A... Temozolomide | 18 Years - 70 Years | NRG Oncology |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
